Beta-caryophyllene mitigates high fat diet-induced testicular dysfunctions by targeting JNK/ERK-1 and JAK-1/STAT-3 pathways in rats Authors: Alaa Muqbil Alsirhani, Othman R Alzahrani, Amal S Abu-Almakarem, Noorah Saleh Al-Sowayan, Afnan M Shakoori, Aljazi Abdullah AlRashidi, Salwa Aljohani, Rabab Mohamed Aljarari, Safaa Abdullah Alowaidi, Maysa A Mobasher, Karim Samy El-Said Published: 2026 ABSTRACT AbstractObesity exacerbates metabolic alterations, increasingly linked to male reproductive dysfunction through oxidative stress and inflammatory signaling. β-caryophyllene (BCP) has shown several biological activities due to its antioxidant potential. This study addressed the efficacy of BCP treatment in ameliorating testicular dysfunctionality in obese male rats. Forty male rats were used as follows: G1 as a negative control, fed on a balanced diet; Gps2-5 were fed on a high-fat diet (HFD) for 12 weeks. G2 acted as a positive control. Subsequently, Gps3-5 were administered intraperitoneally (i.p.) with BCP at doses of 25, 50, and 75 mg/kg, respectively for 8 weeks following 12 weeks of HFD induction. After 20 weeks, spermatological parameters, hormone profiles, oxidative stress markers, inflammatory cytokines, expression of JNK/ERK-1 and JAK-1/ STAT-3 pathway components, and testicular histopatholog were assessed. The HFD significantly impaired reproductive parameters, with decreased sperm count, motility, and testosterone levels and increased oxidative stress markers, including malondialdehyde (MDA), and pro-inflammatory cytokines. BCP treatment dose-dependently ameliorated these alterations, with the highest dose restoring sperm count and motility and significantly elevating testosterone levels. BCP downregulated the overexpression of JNK/ERK-1 and JAK-1/STAT-3 signaling pathways. Histopathological examination confirmed marked improvement in testicular architecture in BCP-treated groups. Collectively, BCP treatment effectively mitigates HFD-induced testicular dysfunction via antioxidant, anti-inflammatory, and targeted testicular JNK/ERK-1 and JAK-1/ STAT-3 pathways in obese rats. These findings highlight its potential as a therapeutic candidate for obesity-associated male reproductive impairment.Keywords: Beta-caryophyllene, Antioxidant, Anti-inflammatory, Obesity, Testis, Signaling pathwaysSubject terms: Biochemistry, Endocrinology, Physiology Introduction Obesity is a major global metabolic health issue contributing to various comorbidities, including male infertility1. This metabolic condition increases the risk of a range of disorders, including diabetes, hypertension, liver disease, and infertility, which, in turn, reduces the overall lifespan2. Obesity and male reproductive abnormalities have been linked in epidemiological studies3. A high-fat diet (HFD) has been related to the development of obesity through food overconsumption and weight gain, which is associated with biochemical and histopathological abnormalities4. This HFD damages testicular functioning by increasing oxidative stress and activating pro-inflammatory signaling pathways5. Increased oxidation, inflammation, and apoptosis, as well as altered endocrine profiles, are the main factors linked to testicular dysfunctions in obesity conditions6. Male obesity is gradually linked to a decline in sperm quality and testicular germ cells, as well as a decrease in sperm motility and testosterone levels and an increase in sperm abnormalities7. It has been demonstrated that a HFD altered testicular activity and blood-testis barrier integrity, impaired steroidogenesis, spermatogenesis, and modulated the MAPK signaling pathways in obese rats8. Furthermore, the role of the JNK pathway has been reported in HFD-induced obesity in male rats9. Pharmacological treatments for obesity mostly target metabolic indicators and weight loss, however there is still a therapeutic gap when it comes to treating secondary problems such testicular dysfunction brought on by obesity. Certain pro-inflammatory cascades are triggered by metabolic stress and directly hinder spermatogenesis and steroidogenesis. Therefore, maintaining male fertility under stress caused by a high-fat diet requires the identification of bioactive substances that precisely target these signaling pathways inside the testicular microenvironment10. Recently, natural constituents have been employed, and numerous research studies have demonstrated their value in the treatment of obesity and its associated conditions11–13. The clinical evidence for these natural compounds is increasingly solid, and their molecular mechanisms, and signaling pathways have been shown to interact with the endocrine and gastroenteric systems13. Treatment with natural constituents led to a significant mitigation of testicular dysfunctions and modulated the JAK-1/STAT-3 pathway in the rats14,15. Liraglutide has been reported to alleviate testicular dysfunction by modulating TGF-β/Smad signaling pathways in male rats16. Deoxynojirimycin was reported to mitigate testicular inflammation induced by obesity by inhibiting the IKKβ/ NF-kB pathway in experimental animals17. Memantine attenuated oxidative stress in the testicular tissues in rats by regulating the ERK1/2-Nrf2 signaling pathway18. Beta-caryophyllene (BCP) found in various plant essential oils, belongs to the cannabinoid family and has demonstrated potential anti-inflammatory and antioxidant properties19. An LD50 of more than 5000 mg/kg has been established in studies on the acute toxicity of BCP in rats20. Unlike other cannabinoids, BCP is a unique sesquiterpene that acts as a selective functional agonist of the cannabinoid type 2 receptor (CB2R). It exerts potent anti-inflammatory effects without inducing the psychoactive side effects associated with CB1 receptor activation. The endocannabinoid system, particularly through CB2 receptors, plays a pivotal role in regulating male reproductive health, including the modulation of the blood-testis barrier and the protection of germ cells from systemic metabolic stress. Given that BCP is highly lipophilic, it possesses the ability to effectively penetrate lipid-rich environments, such as those exacerbated by a high-fat diet, potentially offering localized protection within the testicular microenvironment. Moreover, the antioxidant profile of BCP is particularly relevant in the context of metabolic disorders. Beyond its role as a CB2 agonist, BCP acts as a potent scavenger of free radicals. This reduction in the oxidative load is crucial; therefore, BCP’s antioxidant capacity may serve as the primary switch that prevents the subsequent inflammatory and apoptotic signaling leading to male infertility. According to preclinical research, BCP significantly reduced the detrimental consequences of vascular inflammation and dyslipidemia in mice21. The hypo-cholesterolemic effect of BCP has been reported in rats fed a cholesterol and fat enriched diet22. Dietary cannabinoid BCP has been demonstrated to prevent immune dysregulation in an obesity mouse model23. Additionally, BCP showed therapeutic potential against diabetes and associated complications24. A study by Hashiesh et al. (2023) demonstrated that BCP could mitigate diabetic cardiomyopathy in mice25. Interestingly, BCP demonstrated potential protective effects against damage to the male reproductive system in mice caused by cadmium chloride26. The activation of JNK and ERK1/2 pathways is primarily associated with testicular injury in rats27. The JAK/STAT pathway regulates male reproductive processes; their activation led to the inhibition of the spermatogenic process14. Natural compounds reduced testicular inflammation by inhibiting JAK-STAT signaling28. At the molecular level, BCP has been shown to suppress the phosphorylation of various mitogen-activated protein kinases (MAPKs). BCP can downregulate the JNK pathways, which are primary drivers of cellular apoptosis and oxidative damage, BCP prevents glioblastoma cell proliferation by direct modulation of CB2 receptors. Furthermore, BCP’s ability to interfere with the signaling cascades has been observed in inflammatory contexts, suggesting it may inhibit the transcription of pro-inflammatory cytokines that typically lead to spermatogenic arrest29. Although BCP has demonstrated multiple pharmacological properties, its role in obesity-associated testicular dysfunction remains unexplored. To the best of our knowledge, this is the first study to investigate the dose-dependent effects of BCP against high-fat diet-induced testicular dysfunction in male rats, with an emphasis on its concurrent modulation of oxidative stress, inflammatory responses, and JNK/ERK-1 and JAK-1/STAT-3 signaling pathways. Results Interactions of BCP with JNK, ERK-1, JAK-1, and STAT-3 proteins through molecular docking The docking simulations revealed that BCP binds to signaling pathway-related proteins with varying strengths, showing binding energies ranging from − 5.8 to -6.7 kcal/mol. JNK protein displayed the strongest binding affinity (-6.7 kcal/mol), followed by ERK-1 (-6.6 kcal/mol) and JAK-1 (-6.4 kcal/mol). STAT-3 showed moderate binding strength (-5.8 kcal/mol) (Table 1). The strong binding of BCP to JNK and ERK-1 is significant because these proteins play promising roles in various biological processes, including those within testicular tissues. Their activation can lead to testicular dysfunctions and inflammation. The interaction with JAK-1 involved ALA772 at 4.45 Å, a residue that may be located in a regulatory region of the kinase. This binding pattern suggested that BCP acts as an allosteric modulator rather than directly competing with ATP binding. This mechanism could offer advantages in terms of selectivity, as allosteric sites tend to be more unique among different kinases compared to the highly conserved ATP-binding sites. Table 1The binding affinity and ∆G (Kcal/mol) for BCP with JNK, ERK-1, JAK-1, and STAT-3 proteins.ProteinsBCPJNK-6.7ERK-1-6.6JAK-1-6.4STAT-3-5.8JNK: c-Jun N-terminal kinase, ERK: Extracellular signal regulated kinase, JAK: Janus kinase, STAT: Signal transducer and activator of transcription. The binding affinity and ∆G (Kcal/mol) for BCP with JNK, ERK-1, JAK-1, and STAT-3 proteins. JNK: c-Jun N-terminal kinase, ERK: Extracellular signal regulated kinase, JAK: Janus kinase, STAT: Signal transducer and activator of transcription. The JNK binding involved two simultaneous contacts with ILE32 and VAL40, both at approximately 5.1 Å. This dual interaction pattern suggested that the compound spans between two hydrophobic regions, creating a bridge-like binding mode that could effectively lock the protein in a particular conformation. The symmetrical nature of these interactions implies a stable binding geometry that could provide sustained modulation of JNK activity (Fig. 1A). In the ERK-1 complex, BCP interacted with two hydrophobic residues, including VAL57 at 4.01 Å and LEU174 at 5.40 Å. The close contact with VAL57 suggested a particularly strong interaction that likely contributes significantly to binding stability. These interactions indicated that BCP occupied a hydrophobic pocket within ERK-1, where it could interfere with normal protein function by either blocking substrate binding or stabilizing an inactive conformation (Fig. 1B). The interaction with STAT-3 involved HIS332 through a pi-alkyl contact at 5.43 Å. This interaction type combines hydrophobic stabilization with some directional preference due to the aromatic-aliphatic nature of the contact. Such interactions often provide both stability and specificity, suggesting that BCP might selectively modulate STAT-3 compared to other STAT family members (Fig. 1C, D). (A, B) The interactions of BCP with JNK and ERK-1 proteins (2D) and (3D). (A) BCP with JNK (-6.7), the hydrophobic interactions, Alkyl (ILE32 and VAL40). (B) BCP with ERK-1 (-6.6), the hydrophobic interactions, Alkyl (VAL57 and LEU174). (C, D) The interactions of BCP with JAK-1 and STAT-3 proteins (2D) and (3D). (C) BCP with JAK-1 (-6.4), the hydrophobic interactions, Alkyl (ALA772). (D) BCP with STAT-3 (-5.8), the hydrophobic interactions, Alkyl (HIS332). In-silico ADMET analysis for BCP The BCP exhibited high lipophilicity (LogP = 5.341), which typically enhances cell membrane penetration and intracellular target access. However, this characteristic also led to very poor water solubility (LogS = -5.81). The absorption profile presented a paradox: despite high lipophilicity suggesting good membrane permeability, the compound displayed low Caco-2 permeability (-4.611). This categorizes BCP as a class II compound in pharmaceutical terms, where permeability is considered adequate. The compound also demonstrated BBB permeability = 0.557. While protein binding can extend drug circulation, it often requires higher doses to achieve therapeutic free drug concentrations. Additionally, the short half-life (0.1 h) indicates rapid elimination from the body, necessitating frequent dosing or specialized formulations to maintain therapeutic levels. Despite rapid elimination, the compound exhibited relatively low clearance (5.458 mL/min/kg), suggesting that the rapid disappearance is due to distribution rather than metabolism or excretion. The moderate volume of distribution (2.514 L/kg) indicated reasonable tissue penetration, consistent with its lipophilic properties (Table 2). Table 2ADMET analysis for BCP therapeutic and bioavailability.PropertyValueInterpretation Therapeutic and bioavailability LogP5.341The compound is highly lipophilic, suggesting good membrane permeabilityLogS-5.81Very low aqueous solubilityHIA0.004Low human intestinal absorptionBBB permeability0.557Can cross the blood-brain barrierPlasma protein binding (PPB)92.17%Highly bound to plasma proteinsVolume of distribution (VDss)2.514 L/kgModerate volume of distributionClearance (CL)5.458 mL/min/kgLow clearance from the bodyHalf-life (T1/2)0.1 hVery short half-life, indicating rapid eliminationCYP substratesCYP2C19 (0.829), CYP2D6 (0.766)Metabolized by key cytochrome P450 enzymeshERG inhibition0.019Low risk of cardiotoxicity Toxicity and safety DILI0.131Low potential for drug-induced liver injuryAmes test0.004Low risk of mutagenicityCarcinogenicity0.065Low risk of causing cancerEndocrine disruptor (EC)0.661Predicted to be an endocrine disruptorBioconcentration factor (BCF)3.314Low potential to accumulate in living organismsLC506.125 mg/LModerate acute aquatic toxicity ADMET analysis for BCP therapeutic and bioavailability. Toxicology predictions suggested a generally favorable safety profile for BCP with a few exceptions. BCP showed low potential for DILI = 0.131, minimal mutagenic risk (Ames = 0.004), and low carcinogenic potential (0.065). The low hERG inhibition score (0.019) indicated minimal risk of dangerous heart rhythm abnormalities, which are common causes of drug development failures and clinical safety concerns. The environmental toxicity profile indicated that BCP poses risks to aquatic organisms, with moderate acute toxicity (LC50 = 6.125 mg/L). While this does not directly impact human therapeutic use the low bioconcentration factor (3.314) provided some reassurance by indicating that the compound does not accumulate extensively in living organisms (Fig. 2). Radar chart for ADMET screening showing the upper, lower, and predicted values of various physicochemical and molecular properties of BCP. Treatment with BCP ameliorated changes in body weight, epididymis, and testis weights of obese rats A significant increase was reported in the body weigh change (%) of rats administered with HFD up to 203.12% compared to the normal control (89.09%). However, the obese groups that were treated with different doses of BCP showed a significant improvement in body weight (P < 0.0001 and η² > 0.8) compared to the obese group alone (Fig. 3A). Additionally, there were significant reductions (P < 0.0001 and η² > 0.8) in the testicular and epididymal weights of the obese group compared to the normal control. The weights of the testicles and epididymis of the rats fed on a HFD significantly improved after receiving BCP treatment (Fig. 3B). (A) The initial, final body weights and the % b. wt. changes. (B) The epididymis and testis weights in the different groups. G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group; I.B.W: Initial body weight; F.B.W: Final body weight; BCP: Beta-caryophyllene. Data was expressed as mean ± S.D. (n = 8). Statistical significance is indicated by superscript letters (a, b, c, d, e); means within the same row/parameter not sharing a common letter are significantly different based on One-way ANOVA followed by [Tukey’s] post-hoc test. One-way ANOVA revealed a highly significant difference in body weight gain among the experimental groups (P < 0.0001 and η² > 0.8), indicate that group membership explains > 80% of the variance, which is a strong effect size. BCP treatment enhanced the obese rats’ spermatological parameters The HFD-fed group exhibited marked impairments in spermatological parameters compared to the normal control. Sperm count decreased significantly in the HFD control (P < 0.0001, η² = 0.951) to 38.51 ± 2.86 × 10⁶/mL compared to the normal control (77.82 ± 3.94 × 10⁶/mL). Similarly, sperm motility dropped from 88.67 ± 4.35% to 51.23 ± 3.86% (P < 0.0001, η² = 0.944), accompanied by a significant increase in sperm abnormalities (9.86 ± 1.23% vs. 26.29 ± 1.96%, P < 0.0001, η² = 0.954). Additionally, sperm viability was significantly reduced (68.95 ± 3.83% vs. 33.49 ± 2.95%, P < 0.0001, η² = 0.948). Administration of BCP to HFD-fed rats significantly improved all spermatological parameters in dose dependent manner (Table 3). Table 3Treatment with BCP ameliorated spermatological alterations of obese rats.GroupsCount (x 106/mL)Motility (%)Abnormality (%)Viability (%)G177.82 ± 3.94a88.67 ± 4.35c9.86 ± 1.23b68.95 ± 3.83dG238.51 ± 2.86c51.23 ± 3.86a26.29 ± 1.96d33.49 ± 2.95aG349.63 ± 2.59d65.32 ± 3.75b21.15 ± 1.78d, c45.13 ± 3.16cG457.94 ± 3.17d73.69 ± 4.21b, c13.87 ± 1.38b60.28 ± 3.61dG568.85 ± 3.75a81.93 ± 3.95c11.58 ± 1.45b63.18 ± 3.25dData was expressed as mean ± S.D. (n = 8). G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group; BCP: Beta-caryophyllene. Different superscript letters (a-d) indicate significant differences between groups. One-way ANOVA revealed significant differences among experimental groups in sperm count (P < 0.0001, η² = 0.951), motility (P < 0.0001, η² = 0.944), abnormality (P < 0.0001, η² = 0.954), and viability (P < 0.0001, η² = 0.948). Treatment with BCP ameliorated spermatological alterations of obese rats. Data was expressed as mean ± S.D. (n = 8). G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group; BCP: Beta-caryophyllene. Different superscript letters (a-d) indicate significant differences between groups. One-way ANOVA revealed significant differences among experimental groups in sperm count (P < 0.0001, η² = 0.951), motility (P < 0.0001, η² = 0.944), abnormality (P < 0.0001, η² = 0.954), and viability (P < 0.0001, η² = 0.948). BCP treatment decreases serum lipid profile in obese rats The HFD-fed group showed markedly elevated cholesterol (P < 0.0001, η² = 0.961), triglycerides (P < 0.0001, η² = 0.958), and low density lipoprotein (LDL) (P < 0.0001, η² = 0.953) levels while significantly reducing high denisty lipoprotein (HDL) (P < 0.0001, η² = 0.945) levels. However, BCP treatment showed a dose-dependent improvement in lipid metabolism. BCP at 50 mg/kg significantly restored lipid levels (P < 0.0001), while BCP at 75 mg/kg showed the strongest effect, nearly normalizing serum lipids to control levels (Table 4). Table 4Treatment with BCP decreases serum lipids profile of obese rats.GroupsCholesterol (mg/dL)Triglycerides (mg/dL)LDL (mg/dL)HDL (mg/dL)G1116.46 ± 6.68a87.69 ± 4.84c27.77 ± 2.63b49.67 ± 2.95dG2218.89 ± 10.35d169.15 ± 9.76d86.93 ± 3.95d22.38 ± 2.14aG3184.57 ± 9.44b142.37 ± 8.52b69.54 ± 4.57a28.92 ± 2.57a, cG4151.98 ± 6.38c115.84 ± 6.31a49.37 ± 3.56c35.49 ± 3.25cG5128.7 ± 6.83a95.16 ± 5.43c35.88 ± 2.95b, c42.05 ± 3.86c, dData was expressed as mean ± S.D. (n = 8). G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group; BCP: Beta-caryophyllene. Different superscript letters (a-d) indicate significant differences between groups. One-way ANOVA revealed highly significant differences among experimental groups in total cholesterol (P < 0.0001, η² = 0.961), triglycerides (P < 0.0001, η² = 0.958), LDL (P < 0.0001, η² = 0.953), and HDL levels (P < 0.0001, η² = 0.945). Treatment with BCP decreases serum lipids profile of obese rats. Data was expressed as mean ± S.D. (n = 8). G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group; BCP: Beta-caryophyllene. Different superscript letters (a-d) indicate significant differences between groups. One-way ANOVA revealed highly significant differences among experimental groups in total cholesterol (P < 0.0001, η² = 0.961), triglycerides (P < 0.0001, η² = 0.958), LDL (P < 0.0001, η² = 0.953), and HDL levels (P < 0.0001, η² = 0.945). BCP treatment increases reproductive hormones in obese male rats Obese rats demonstrated significant reductions in their FSH (P < 0.0001, η² = 0.935), LH (P < 0.0001, η² = 0.910), and testosterone (P < 0.0001, η² = 0.942) hormonal levels compared to the normal control. However, treatment with BCP at dosages of 50 and 75 mg/kg led to significant restoration (P < 0.0001) in these male reproductive hormonal levels close to the normal values compared to the obese group alone or obese/BCP (25 mg/kg) treated group (Fig. 4). Serum hormonal levels. (A) Follicular stimulating hormone (FSH), (B) Luteinizing hormone (LH), and (C) Testosterone. G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group; BCP: Beta-caryophyllene. Data was expressed as mean ± S.D. (n = 8). Different superscript letters (a-d) indicate significant differences between groups. One-way ANOVA revealed highly significant differences among experimental groups in FSH (P < 0.0001, η² = 0.935), LH (P < 0.0001, η² = 0.910), and testosterone (P < 0.0001, η² = 0.942). Treatment with BCP improves antioxidant status in testicular tissues of obese rats The levels of superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH), and sorbitol dehydrogenase (SDH) in the obese group were significantly lower (P < 0.0001) than those in the control group. Administering BCP to obese rats in a dose-dependent manner resulted in a significant restoration of these levels (Table 5). The testicular MDA and PC levels in the obese group induced by HFD were significantly higher than those in the control group. However, after receiving BCP, their testicular MDA and PC levels decreased with the most notable improvement seen at a dosage of 75 mg/kg (MDA, P < 0.0001, η² = 0.970 and PC, P < 0.0001, η² = 0.965) (Fig. 5). Table 5Effect of BCP on testicular antioxidant parameters of obese rats.GroupsSOD(U/mg protein)CAT(U/mg protein)GSH(mmol/g tissue)SDH(mmol/mg protein)G12.89 ± 0.24b59.74 ± 3.45a9.63 ± 0.75a1.25 ± 0.09cG20.94 ± 0.11c25.39 ± 2.31b3.28 ± 0.36c0.51 ± 0.06aG31.38 ± 0.15a34.68 ± 2.29c4.67 ± 0.50d0.74 ± 0.05bG41.97 ± 0.20a, b46.28 ± 3.52a, d6.92 ± 0.58b0.98 ± 0.07b, cG52.56 ± 0.21b52.17 ± 3.37a8.74 ± 0.69a1.09 ± 0.08cData was expressed as mean ± S.D. (n = 8). SOD: Superoxide dismutase; CAT: Catalase; GSH: Reduced glutathione; SDH: sorbitol dehydrogenases; BCP: Beta-caryophyllene; G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group. Different superscript letters (a-d) indicate significant differences between groups. One-way ANOVA revealed highly significant differences among experimental groups in SOD (P < 0.0001, η² = 0.914), CAT (P < 0.001, η² = 0.890), GSH (P < 0.0001, η² = 0.902), and SDH levels (P < 0.0001, η² = 0.925). Effect of BCP on testicular antioxidant parameters of obese rats. Data was expressed as mean ± S.D. (n = 8). SOD: Superoxide dismutase; CAT: Catalase; GSH: Reduced glutathione; SDH: sorbitol dehydrogenases; BCP: Beta-caryophyllene; G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group. Different superscript letters (a-d) indicate significant differences between groups. One-way ANOVA revealed highly significant differences among experimental groups in SOD (P < 0.0001, η² = 0.914), CAT (P < 0.001, η² = 0.890), GSH (P < 0.0001, η² = 0.902), and SDH levels (P < 0.0001, η² = 0.925). Effect of BCP on testicular oxidative stress of obese rats. (A) MDA and (B) Protein carbonyl (PC). G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group; BCP: Beta-caryophyllene. Data was expressed as mean ± S.D. (n = 8). Groups labeled with different letters are significantly different from one another according to [Tukey’s] multiple range test. One-way ANOVA revealed highly significant differences among experimental groups in MDA (P < 0.0001, η² = 0.970) and PC levels (P < 0.0001, η² = 0.965). Anti-inflammatory effects of BCP in HFD-induced testicular injury in rats The HFD-induced obese rats had considerably higher levels (P < 0.0001) of the testicular inflammatory cytokines (IL-6, TNF-α, COX-2, and NF-κB) than the normal control group. When BCP was administered to obese rats, these inflammatory indicators significantly decreased (P < 0.0001) in a dose-dependent manner, reaching near-control levels at the higher dose (Table 6). Table 6Effect of BCP treatment on the testicular inflammatory biomarkers of obese rats.GroupsIL-6(pg/ml/mg protein)TNF-α(pg/ml/mg protein)COX-2(ng/g protein)NF-κB(ng/mg tissue)G127.38 ± 1.95a32.64 ± 2.95c223.68 ± 5.53d20.93 ± 1.75bG278.46 ± 4.23b89.21 ± 3.64d563.47 ± 8.93b62.63 ± 3.55aG365.93 ± 3.48c76.13 ± 4.28e441.17 ± 6.38c45.17 ± 3.28a, cG448.62 ± 3.56a, d55.36 ± 3.92a319.28 ± 7.05e34.95 ± 2.54cG535.65 ± 3.44a38.45 ± 3.28c291.38 ± 6.82a23.17 ± 1.93bData was expressed as mean ± S.D. (n = 8). IL-6: Interleukin 6; TNF-α: Tumor necrosis factor alfa; COX-2: Cyclooxygenase-2; NF-κB: Nuclear factor kappa beta; BCP: Beta-caryophyllene. Different superscript letters (a-e) indicate significant differences between groups. One-way ANOVA revealed highly significant differences among experimental groups in IL-6 (P < 0.0001, η² = 0.961), TNF-α (P < 0.0001, η² = 0.953), COX-2 (P < 0.0001, η² = 0.974), and NF-κB levels (P < 0.0001, η² = 0.945). Effect of BCP treatment on the testicular inflammatory biomarkers of obese rats. Data was expressed as mean ± S.D. (n = 8). IL-6: Interleukin 6; TNF-α: Tumor necrosis factor alfa; COX-2: Cyclooxygenase-2; NF-κB: Nuclear factor kappa beta; BCP: Beta-caryophyllene. Different superscript letters (a-e) indicate significant differences between groups. One-way ANOVA revealed highly significant differences among experimental groups in IL-6 (P < 0.0001, η² = 0.961), TNF-α (P < 0.0001, η² = 0.953), COX-2 (P < 0.0001, η² = 0.974), and NF-κB levels (P < 0.0001, η² = 0.945). Treatment with BCP targeting JNK/ERK-1 and JAK-1/STAT-3 pathways in obese rats Rats fed a HFD displayed significant upregulation (P < 0.0001) of JNK (2.9-fold), ERK-1 (2.5-fold), JAK-1 (3.4-fold), and STAT-3 (3.9-fold) expressions. Treatment with BCP effectively reversed these changes (Table 7). Rats co-treated with HFD + BCP (75 mg/kg) exhibited a pronounced downregulation (P < 0.0001) of JNK (2.4-fold), ERK-1 (1.9-fold), JAK-1 (2.00-fold), and STAT-3 (2.1-fold). Testicular homogenates from HFD-fed rats had significantly higher levels of the proteins p-JNK, p-ERK1, p-JAK1, and p-STAT3 than the control group. On the other hand, BCP administration led to a significant (P < 0.0001) dose-dependent decrease in the expression of these proteins (Fig. 6). Table 7Effect of BCP treatment on the mRNA expression levels of JNK, ERK-1, JAK-1, and STAT-3 genes in obese rats.GroupsJNKERK-1JAK-1STAT-3G11.00 ± 0.03a1.00 ± 0.02c1.00 ± 0.01b1.00 ± 0.04cG22.90 ± 0.18b2.50 ± 0.18d3.40 ± 0.29a3.90 ± 0.32dG32.23 ± 0.15c2.00 ± 0.16b2.95 ± 0.24c3.40 ± 0.28eG41.71 ± 0.16d1.51 ± 0.14e2.25 ± 0.19d2.35 ± 0.22bG51.20 ± 0.11a1.30 ± 0.12c, e1.70 ± 0.18e1.85 ± 0.19aData was expressed as mean ± S.D. (n = 8). JNK: c-Jun N-terminal kinase, ERK: Extracellular signal regulated kinase, JAK: Janus kinase, STAT: Signal transducer and activator of transcription. Means that do not share a letter in each column showed significant difference. One-way ANOVA revealed highly significant differences among experimental groups in JNK (P < 0.0001, η² = 0.950), ERK-1 (P < 0.0001, η² = 0.942), JAK-1 (P < 0.0001, η² = 0.961), and STAT-3 levels (P < 0.0001, η² = 0.975). Effect of BCP treatment on the mRNA expression levels of JNK, ERK-1, JAK-1, and STAT-3 genes in obese rats. Data was expressed as mean ± S.D. (n = 8). JNK: c-Jun N-terminal kinase, ERK: Extracellular signal regulated kinase, JAK: Janus kinase, STAT: Signal transducer and activator of transcription. Means that do not share a letter in each column showed significant difference. One-way ANOVA revealed highly significant differences among experimental groups in JNK (P < 0.0001, η² = 0.950), ERK-1 (P < 0.0001, η² = 0.942), JAK-1 (P < 0.0001, η² = 0.961), and STAT-3 levels (P < 0.0001, η² = 0.975). The protein levels of p-JNK (A), p-Erk1 (B), p-Jak1 (C), and p-STAT3 (D). G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group; BCP: Beta-caryophyllene. Data was expressed as mean ± S.D. (n = 8). Different superscript letters (a-d) indicate significant differences between groups. One-way ANOVA revealed highly significant differences among experimental groups in p-JNK (P < 0.0001, η² = 0.953), p-Erk1 (P < 0.0001, η² = 0.975), p-Jak1 (P < 0.0001, η² = 0.950), and p-STAT3 levels (P < 0.0001, η² = 0.950). BCP treatment mitigates histopathological alterations in obese rats The testicular sections from the negative control group showed normal histological structures of mature seminiferous tubules, regular interstitial Leydig cells, and active Sertoli cells (Fig. 7A). Testicular sections of the obese group showed significant alterations, including testicular vessel congestion, irregular basement membrane, absence of spermatogenic series, and disrupted seminiferous tubules (Fig. 7B). However, testicular sections from the HFD/BCP-treated groups showed a notable restoration of the architectures of most seminiferous tubules, along with an improved Leydig cell spermatogenesis process (Fig. 7C-E). The HFD-administered group’s testis section Johnsen score was significantly lower ; however, the HFD/BCP group’s score results were significantly higher (P < 0.0001, η² = 0.945) (Fig. 7F). Photomicrographs of testicular sections from different groups. (A) Shows testis sections from the control group, indicating normal testicular structures, normal luminal sperms (solid arrows), and spermatogonial layers (dotted arrows). (B) Shows a section of the obese group, with congested testicular vessels, defective spermatogenic series in the seminiferous tubules (*), irregular seminiferous tubules, and degeneration of spermatogenic epithelial series (red arrows). (C-E) Show testicular sections of the HFD + BCP-treated group at dosages of 25, 50, and 75 mg/kg, respectively with a mitigative effect on testicular histopathology, restored seminiferous tubule structures, and maintained spermatogonia cells. (F) Effects of BCP treatment on Johnsen testicular score. G1: Normal control group; G2: Obese group; G3: Obese/BCP (25 mg/kg) group; G4: Obese/BCP (50 mg/kg) group; G5: Obese/BCP (75 mg/kg) group; BCP: Beta-caryophyllene. Data was expressed as mean ± S.D. (n = 8). Different superscript letters (a-c) indicate significant differences between groups. One-way ANOVA revealed highly significant differences among experimental groups in Johnsen score (P < 0.0001, η² = 0.945). Discussion Beta-caryophyllene, a sesquiterpene found in many plants including cannabis, cloves, and black pepper, has shown anti-inflammatory, antioxidant, and anticancer effects in laboratory studies22–26,29. However, researchers have not thoroughly examined the mechanisms of its effects against testicular dysfunctions in obese rats. Therefore, this study investigated the ameliorative effects of BCP on testicular injury of obese rats and their mechanisms, which could serve as an effective anti-obese agent in clinical settings. The results of docking simulations indicated that BCP forms stable complexes with JNK, ERK-1, JAK-1, and STAT-3 proteins, suggesting genuine biological interactions rather than random binding events. BCP’s ability to bind strongly to JNK suggests it might restore the protein’s normal function, ameliorating testicular damage induced by HFD. The ERK-1 protein represented another critical target, as this protein drives many of the fundamental processes in testicular tissue proliferation. When ERK signaling becomes overactive, cells divide uncontrollably and resist death signals27. The strong binding affinity between BCP and ERK-1 indicated the capability of BCP to interfere with this protein cascade, potentially regulating Sertoli cells differentiation. The JAK-1 and STAT-3 proteins serve as central hubs for cytokine signaling, which affects testicular inflammatory responses14. The ability of BCP to bind effectively to JAK-1 and STAT-3 proteins suggested it might disrupt these signals, leading to enhanced immune surveillance30. The detailed interaction analysis showed that BCP forms exclusively hydrophobic contacts with its protein targets, which matches expectations based on its chemical structure. The BCP established alkyl and pi-alkyl interactions at distances ranging from 4.01 to 5.47 Å, indicating optimal spacing for stable van der Waals forces without steric conflicts. These hydro-phobic interactions depend on the compound’s cyclic structure and methyl groups, which appear essential for binding specificity. The JAK-1 interaction involved ALA772 at 4.45 Å, a residue that may reside in a regulatory region of the kinase. This binding pattern suggests BCP acts as an allosteric modulator rather than competing directly with ATP binding. This mechanism could offer advantages in terms of selectivity, as allosteric sites tend to be more unique between different kinases compared to the highly conserved ATP-binding sites. While our molecular docking analysis demonstrated favorable binding affinities and stable interaction patterns between BCP and its targets (JNK, ERK-1, JAK-1, and STAT-3), we acknowledge that docking represents a static model of interaction. Further biophysical characterization using Molecular Dynamics (MD) simulations and MM/PBSA binding free energy calculations would provide deeper insights into the time-dependent stability and conformational changes of these complexes. However, the strong correlation between our in silico predictions and the significant vivo modulation of these signaling pathways in our rat model provides compelling evidence of BCP’s functional relevance as a multi-target inhibitor of obesity-induced testicular dysfunction. When combining the molecular docking results with the pharmacokinetic analysis, a complex therapeutic profile emerges. The strong binding affinities to multiple proteins provide solid molecular justification for the compound’s reported biological activities31. The multi-target binding pattern suggested that BCP functions as what pharmacologists call a “promiscuous” compound one that beneficially interacts with multiple targets rather than selectively hitting a single pathway. This multi-target approach aligns well with cancer biology, where the complexity and redundancy of tumor-promoting pathways often limit single-target therapies. By simultaneously engaging JNK, ERK-1, JAK-1, and STAT-3; BCP could potentially create a coordinated modulation of cellular mechanisms. This comprehensive pathway interference could produce synergistic effects that exceed what would be expected from targeting any single protein. The rapid elimination kinetics, while challenging for maintaining drug levels, could provide safety advantages by minimizing accumulation-related toxicities. The short half-life means any adverse effects would likely be brief, and the compound would clear quickly if toxicity occurred32. Administration of HFD resulted in a marked increase in body weight gain in obese rats, along with a notable reduction in testicular and epididymal weights. These findings are consistent with earlier reports showing that diet-induced obesity impairs reproductive organ development and function by disrupting energy homeostasis in testicular tissues33–35. The reduced testicular and epididymal weights observed in the obese group may be attributed to impaired spermatogenesis and altered androgen production, which are common features of obesity-associated hypogonadism36. Treatment with BCP significantly improved these changes. BCP administration not only reduced the excessive body weight gain caused by the HFD but also enhanced testicular and epididymal weights. These beneficial effects can be explained by BCP’s role as a natural dietary cannabinoid and selective cannabinoid receptor agonist, known to regulate energy balance, adipogenesis, and inflammation. BCP supplementation can inhibit lipid synthesis, leading to reduced weight gain and adiposity24,37. The HFD-induced obesity led to significant impairments in spermatological parameters, including a decrease in sperm count, motility, and viability, as well as an increase in abnormal spermatozoa. These changes align with previous report showing that obesity can negatively impact male fertility through various mechanisms such as oxidative stress, endocrine disruption, lipid accumulation in reproductive tissues, and inflammation38. The significant decline in sperm viability observed in the obese group may be attributed to the excessive generation of reactive oxygen species (ROS), which can harm the sperm plasma membrane, mitochondrial function, and DNA integrity. Similarly, the higher proportion of abnormal spermatozoa indicates compromised spermatogenesis, potentially due to changes in the testicular microenvironment and hormonal imbalance associated with obesity39. BCP could mitigate testicular apoptosis and inflammation, thus preserving the cellular processes necessary for normal sperm development. BCP’s protective effects on sperm motility and viability may also involve the stabilization of mitochondrial function. Mitochondria play a crucial role in supplying ATP for flagellar movement, and their dysfunction has been linked to reduced sperm motility in obesity40. Additionally, BCP may enhance sperm viability and motility by stabilizing mitochondrial membrane potential, reducing lipid peroxidation of sperm membranes, and boosting antioxidant enzyme activities. Similar protective effects on male reproductive function have been observed in animal models treated with BCP41. These findings align with previous research indicating that diet-induced obesity in rodents can impair spermatogenesis and sperm function through mechanisms involving oxidative stress, inflammation, and hormonal imbalances, which may be alleviated by natural compounds like BCP42. In the present study, the obese group exhibited significantly elevated cholesterol, triglycerides, and LDL levels, while HDL levels were significantly reduced, confirming obesity-induced dyslipidemia. These findings suggest that BCP has hypolipidemic effects in obese rats, which may help prevent testicular dysfunction caused by a HFD by reducing lipotoxicity and oxidative stress. According to Harb et al. (2018), BCP protects against illnesses caused by hypercholesterolemia by decreasing cholesterol levels in hypercholesterolemic mice22. Additionally, Mani et al. (2022) demonstrated that BCP had promising hypolipidemic effects in HFD-induced type-2 diabetic adult male rats43. The present study demonstrates that BCP supplementation ameliorated HFD-induced testicular dysfunctions by restoring reproductive hormones and enhancing antioxidant defense mechanisms. Consistent with previous reports, HFD-induced obesity led to a significant decrease in serum levels of FSH, LH, and testosterone. These hormonal imbalances may be due to increased oxidative stress, which can interfere with Leydig cell steroidogenesis. The obesity-associated metabolic stress has been shown to impair gonadotropin secretion and reduce testosterone biosynthesis, ultimately leading to hypogonadism and compromised male fertility. Interestingly, treatment with BCP, particularly at doses of 50 and 75 mg/kg, significantly restored these hormonal levels to levels close to those of the normal control group. This suggests that BCP has a dose-dependent efficacy in stimulating testicular steroidogenesis, which might play a crucial role in this effect by modulating testicular endocrine function, reducing systemic inflammation, and enhancing antioxidant status. Moreover, the observed hormonal recovery aligns with earlier studies highlighting the protective effects of plant-derived terpenes in obesity-related reproductive dysfunctions44. In obese rat models, high levels of inflammation, apoptosis, and increased testicular oxidative stress are caused by consumption of HFD6. The restoration of the hormonal axis by BCP is intrinsically linked to its impact on the testicular redox state. In our model, HFD-induced obesity created a ‘pro-oxidant’ microenvironment, evidenced by depleted SOD and CAT levels, elevating MDA and PC levels. This oxidative insult specifically targets the cholesterol-rich membranes of Leydig cells, disrupting testosterone biosynthesis. This oxidative imbalance has been widely linked to testicular damage, sperm dysfunction, and reduced fertility in obese males. By bolstering the antioxidant defense system, BCP effectively ‘shields’ the steroidogenic machinery, providing a physiological explanation for the observed recovery in FSH, LH, and testosterone levels. This highlights BCP not merely as a metabolic regulator, but as a potent cytoprotective agent. BCP supplementation effectively boost-ed both enzymatic and non-enzymatic antioxidant defenses. The most notable improvements were observed in the 75 mg/kg-administered group, where SOD, CAT, and GSH levels were nearly equivalent to those of the control group, along with significant decreases in MDA and PC levels. These findings suggest that BCP has potent free radical scavenging and membrane-stabilizing properties, which help mitigate oxidative insults in testicular tissues. The ability of BCP to restore antioxidant enzyme activities may also contribute to the observed hormonal improvements, as oxidative stress is a key factor in suppressing steroidogenic enzymes and Leydig cell function. These results were aligned with previous studies that have reported the effects of plant-derived natural compounds on testicular dysfunctions induced by obesity in experimental animals45–47. Reproductive dysfunctions are caused by oxidative stress, which triggers cellular signal cascades that initiate numerous inflammatory processes in the testicular tissues48,49. The blood-testicular barrier is disrupted by inflammatory mediators, which alter membrane proteins. Increased levels of IL-6 during inflammation may hinder testosterone production, ultimately limiting the spermatogenesis process and causing germ cells to undergo apoptosis50. In the current investigation, chronic inflammation is often associated with obesity, resulting from metabolic changes and the continuous presence of blood vessels51. Significant palliative effects on testicular inflammation in male rats induced by lead injection were observed when obese rats were treated with BCP. This suggested that BCP may have anti-inflammatory effects on the inflammatory process induced by obesity in male rat testicular tissues, aligning with several preliminary investigations24,25,52–54. It was discovered that the presence of reproductive poisons triggered the JAK/STAT pathway, allowing germ cells to survive. Reducing testicular damage and spermatogenesis was achieved by blocking JAK2 phosphorylation and subsequent inactivation as previously demonstrated in experimental models of testicular injury55. Thus, testicular dysfunction is caused by JAK activation during testicular oxidative stress56. As demonstrated by the notable increase in both mRNA and phosphorylated protein levels, the current study shows that long-term ingestion of a HFD significantly activated the JNK/ERK-1 and JAK-1/STAT-3 signaling pathways in rat testicular tissue. Given that JAK-1/STAT-3 signaling is essential for cytokine-mediated inflammation and oxidative damage, and since JNK and ERK-1 are key regulators of stress responses, apoptosis, and inflammation, this aberrant signaling certainly plays a part in the testicular dysfunction linked to obesity. These findings are in line with earlier research demonstrating that metabolic stress brought on by obesity increases MAPK and JAK/STAT activation, which in turn disrupts spermatogenesis and impairs steroidogenesis in male reproductive organs38,57. Importantly, treatment with BCP significantly attenuated the upregulation of these signaling cascades. The highest dose of BCP (75 mg/kg) nearly normalized the expression of JNK, ERK-1, JAK-1, and STAT-3 to control levels, underscoring its potent modulatory effect. The inhibition of JNK and ERK-1 suggests that BCP protects the testis by mitigating oxidative stress, as JNK activation is known to promote mitochondrial dysfunction and germ cell apoptosis. Similarly, the downregulation of JAK-1 and STAT-3 indicates that BCP suppresses inflammatory signaling, since persistent activation of the JAK/STAT pathway is a hallmark of cytokine-driven testicular inflammation in obese models. The molecular mechanisms underlying these protective effects may be attributed to the dual antioxidant and anti-inflammatory properties of BCP. Previous reports have shown that BCP, a selective CB2 receptor agonist, inhibits NF-κB activation, which could indirectly blunt JAK/STAT-3 signaling58. In addition, by restoring redox balance, BCP likely pre-vents the overactivation of JNK and ERK-1. This aligns with studies where BCP ameliorated organ injury in metabolic syndrome by downregulating STAT pathways, thereby improving tissue functions14,59. Our findings highlight the ability of BCP to modulate obesity-induced testicular dysfunction by targeting two critical pathways: JNK/ERK-1, which primarily governs oxidative stress, and JAK-1/STAT-3, which mediates inflammation and cytokine signaling. The normalization of these pathways suggests that BCP confers a comprehensive protective effect on testicular tissue under metabolic stress. These results not only reinforce the therapeutic potential of BCP as a natural agent for male re-productive health in obesity but also provide novel insights into its molecular mechanism of action. The expression levels in the HFD + BCP group approached those observed in the control group, indicating the ability of BCP to normalize stress- and inflammation-associated signaling pathways. The molecular modulation of signaling pathways by BCP was clearly reflected in the structural preservation of the testicular tissue. Our histopathological analysis revealed that HFD-induced obesity led to severe architectural distortions, including basement membrane irregularity and a marked absence of spermatogenic series features typical of metabolic-induced germ cell depletion. The significant reduction in the Johnsen score in the obese group further quantified this spermatogenic arrest. However, BCP treatment effectively reversed these alterations, maintaining the integrity of the seminiferous tubules and promoting active spermatogenesis60. This histological recovery is likely a direct consequence of BCP’s ability to downregulate the JNK and ERK-1 pathways, which are known to trigger germ cell apoptosis and disrupt the tight junctions of the blood-testis barrier when overactivated by metabolic stress. Furthermore, the notable restoration of interstitial Leydig cells and improved spermatogenesis in BCP-treated rats (as seen in Fig. 7C-E) correlates with the observed restoration of serum testosterone levels. By suppressing the JAK-1/STAT-3 inflammatory axis, BCP likely creates a more favorable microenvironment for Leydig cell steroidogenesis, which is otherwise inhibited by the pro-inflammatory cytokines prevalent in obese models. The high Johnsen score and the normalization of the tubular diameter suggest that BCP not only prevents tissue damage but also fosters a regenerative environment that supports the full maturation of spermatids. These findings provide histopathological evidence that BCP functions as a comprehensive protective agent, shielding the physical ‘niche’ of the sperm from systemic lipotoxicity57. At the pinnacle of this protective mechanism is BCP’s regulation of the JNK/ERK-1 and JAK-1/STAT-3 signaling cascades. Our findings suggest a crosstalk model where HFD-induced oxidative stress activates JNK/ERK to promote apoptosis, while systemic lipotoxicity triggers JAK/STAT to fuel chronic inflammation. BCP’s unique ability to simultaneously inhibit these divergent pathways as supported by our molecular docking and phosphorylation assays represents a multi-hit therapeutic strategy. Furthermore, the ‘solid constructive mechanism’ of BCP involves a cross-talk inhibition between inflammation and oxidative stress. The JAK-1/STAT-3 pathway is traditionally activated by pro-inflammatory cytokines such as IL-6 and TNF-$\alpha$, both of which were elevated in our obese rat model. BCP’s interaction with JAK-1 likely interferes with the recruitment of STAT-3 to the cytokine receptor complex. By preventing STAT-3 phosphorylation and subsequent nuclear translocation, BCP effectively silences the transcription of inflammatory genes. This creates a feedback loop: reduced inflammation leads to lower ROS production, which in turn further minimizes the activation of JNK and ERK-1. This dual-pathway modulation targeting the JNK/ERK apoptotic axis and the JAK/STAT inflammatory axis simultaneously represents a synergistic therapeutic strategy that addresses the multi-faceted nature of obesity-induced testicular injury. By dampening these central hubs, BCP effectively halts the progression from metabolic stress to physical testicular atrophy, as confirmed by the significant improvements in the Johnsen score and seminiferous tubule architecture. Despite the promising findings, there were some limitations of this study that should be acknowledged. The use of HFD-induced obesity model in rats, although widely accepted, does not fully recapitulate the complex pathophysiology of human obesity-associated reproductive dysfunction. Furthermore, the duration of BCP treatment, while sufficient to demonstrate therapeutic effects, may not reflect long-term outcomes associated with chronic administration. Therefore, while the current findings highlight the therapeutic potential of BCP against obesity-induced testicular dysfunction, further studies incorporating advanced mechanistic approaches, long-term safety evaluation, and clinical investigations are warranted to confirm its translational applicability. Conclusion Collectively, these findings suggest that BCP supplementation effectively counteracts HFD-induced obesity and its detrimental effects on male reproduction. By restoring testicular and epididymal mass, male reproductive hormones were mitigated. Treatment with BCP may improve reproductive outcomes in obesity, likely through its antioxidant, anti-inflammatory, metabolic regulatory actions, and modulation of JNK/ERK-1 and JAK-1/ STAT-3 signaling pathways in male rats, thereby preserving sperm production, morphology, and motility. The dose-dependent pattern further supports the pharmacological relevance of BCP, highlighting its impacts against obesity-related reproductive dysfunction in male rats. However, the translational potential of BCP as a therapeutic for human obesity-induced testicular dysfunctions requires further preclinical and clinical studies in the future to address its pharmacokinetics and optimal therapeutic regimens. Materials and methods Chemicals β-Caryophyllene (BCP) (≥ 98%, M.F. C15H24, M.W. 204.35, Cat. no. 87-44-5) was purchased from Sigma-Aldrich in St. Louis, Missouri, USA. BCP was dissolved in a mixture consisting of ethanol, Cremophor EL, and 0.9% saline in a volumetric ratio of 1:1:18, respectively, to ensure complete solubilization and biocompatibility. The intraperitoneal (i.p.) injections tested were at doses of 25 mg/kg, 50 mg/kg, and 75 mg/kg/61. Molecular docking The structure of BCP was retrieved from PubChem ID 20831623, and energy minimization was performed using the MMFF94 force field implemented in Avogadro 1.2.0 software to obtain optimized conformations of the ligands64. To prepare proteins for docking, AutoDock Tools 1.5.7 was used65,66. The structure of the following proteins: JNK (UniProt ID: P49185), ERK-1 (UniProt ID: P21708), JAK-1 (UniProt ID: G3V9W2), and STAT-3 (UniProt ID: P52631) were retrieved from the UniProt database. The docked complexes were analyzed using BIOVIA Discovery Studio Visualizer 2020 (San Diego, CA, USA). ADMET analysis and pharmacokinetics were performed using ADMETLab2.067. Balanced and high-fat diets composition 74.4% carbohydrates, 10% fat, 10% protein, 3.5% mineral mixture, 1% vitamin mixture, and 1% fiber made up the balanced diet that was fed to normal rats. Ad libitum, HFD was composed of 40.6% carbs, 44.6% fat, and 14.8% protein68. Animals and experimental design From the National Research Center in Cairo, Egypt, forty male Sprague Dawley rats weighing 150 ± 10 g at 6 weeks of age were acquired. The investigation was carried out in compliance with the Helsinki and ARRIVE (2.0) guidelines for experimental design, bias minimization, sample size and statistical analyses. Approval for the study was obtained from Tanta University’s Faculty of Science’s Animal Care and Use Committee (IACUC-SCI-TU-0297), Egypt. The rats were divided equally into five groups: G1 (vehicle treated) served as a negative control and was fed a balanced diet; Gps2-5 were fed on a high-fat diet (HFD) for 12 weeks to induce obesity. G2 (vehicle treated) was designated as the positive control. Subsequently, Gps3-5 were administered BCP (25, 50, and 75 mg/kg) i.p., respectively for 8 consecutive weeks from week 12 to week 20 (Fig. 8). The BCP doses (25, 50, and 75 mg/kg) were selected based on their proven efficacy in mitigating oxidative stress and inflammation in various rodent models of metabolic syndrome69. The inclusion of three graduated doses was intended to evaluate the dose-dependency of BCP’s protective effects on testicular architecture and signaling pathways. The treatment duration of 8 weeks was established to ensure sufficient time for the modulation of chronic inflammatory cascades and the restoration of spermatogenic parameters, following the 12-week induction phase of obesity-related dysfunction. After 20 weeks, the rats were euthanized under isoflurane anesthesia, serum samples were obtained, testicular and epididymal tissues were collected. Spermatogenic parameters were assessed. Furthermore, testicular tissues were used for molecular, biochemical, and histopathological investigations. Schematic illustration of experimental design showing the different groups. NBD: Normal Based diet; HFD: High fat diet; BCP: Beta-caryophyllene. Spermatogenic parameters Wells and Awa’s stain were applied to sperm samples to assess any anomalies. To evaluate sperm motility, the diluted epididymal sperm suspension was moved to a hemocytometer and seen under a 400 × light microscope. The eosin stain was used in the dye exclusion test to determine the viability of the sperm70. Biochemical analysis Serum levels of total cholesterol (TC) (Catalogue number: EK720559), and total triglycerides (TG) (Catalogue number: MBS726298) were determined using their specific rat kits from AFG Scientific Co. (Devon Avenue, Itasca IL, USA) and from My-BioSource Co. (Inc., San Diego, CA, USA), respectively. LDL (Catalogue number: 79960), and HDL (Catalogue number: 79970) were determined using their specific rat kits from Crystal Chem Co. (Elk Grove Village, USA). Serum LH (Cat. no. E-EL-R0026), FSH (Cat. no. MBS2021901), and testosterone levels (Cat. no. 80550) were determined by using their ELISA kits. The MDA (Cat. no. MD2529), PC (Cat. no. MBS2600784), SOD (Cat. no. SD2521), SDH (Cat. no. MBS269299), GSH (Cat. no. MBS265966), and CAT (Cat. no. CA2517) were determined in the testicular supernatant using ELISA kits from My-BioSource, Inc., San Diego, CA, USA. Furthermore, IL-6 (Cat. no. E-HSEL-R0004), TNF-α (Cat. no. RAB0479), NF-κB (Cat. no. MBS453975), and COX-2 (Cat. no. MBS266603) were assessed. The p-JNK (Cat. no. MBS3808117), p-ERK1 (Cat. no. MBS3808639), p-Jak1 (Cat. no. MBS1608709), and p-STAT3 (Cat. no. MBS7279223) were also determined in tissue homogenates using rat specific ELISA kit. According to the manufacturers’ specifications, all ELISA kits utilized in this study exhibited high sensitivity and precision. The sensitivity for the lipid and hormonal assays ranged from 0.05 to 1.0 mg/dL, while inflammatory and signaling markers showed sensitivities as low as 1.04 pg/mL. For all assays, the intra-assay coefficient of variation (CV) was less than 10%, and the inter-assay CV was less than 12%, ensuring the robustness and reproducibility of the biochemical data. Molecular analysis The expressions of JNK, ERK1, Jak1, and STAT3 genes were evaluated in testicular tissues using SYBR Green. The primer-blast program was used to prepare the primers from NCBI with GAPDH gene as the housekeeping (Table 8)71. Table 8The forward and reverse primer sequences for RT-PCR.GeneAccession numberForward sequence (5’-3’)Reverse sequence (5’-3’) JNK NM_053829.2CACCACCAAAGATCCCTGACAGCACCTAAAGGAGACGGCTG ERK-1 NM_017347.3TCAAGCCTTCCAACCTCGCAGCCCACAGACCAAA JAK-1 NM_001434540GAGGAATGTACTGGGCGTCTTGCAGCCGGAGAGACATTTT STAT-3 NM_012747CACCCTGAAGCTGACCCAGTATTGCTGCAGGTCGTTGGT GAPDH NM_017008.4CCGCATCTTCTTGTGCAGTGGAGAAGGCAGCCCTGGTAACJNK: c-Jun N-terminal kinase, ERK: Extracellular signal regulated kinase, JAK: Janus kinase, STAT: Signal transducer and activator of transcription, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase. The forward and reverse primer sequences for RT-PCR. JNK: c-Jun N-terminal kinase, ERK: Extracellular signal regulated kinase, JAK: Janus kinase, STAT: Signal transducer and activator of transcription, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase. Histopathological investigations Following a 10% buffered formalin fixation, xylene washing, paraffin wax embedding, and 5 μm sectioning, testis tissues were prepared. H&E staining, light microscopy examination, and digital camera photography were used (Olympus Camedia 5060, Japan)72. The architecture of the Sertoli cells and seminiferous tubules in the testicular sections was evaluated using the Johnsen scoring system73. Statistical analysis The parametric data were analyzed using one-way ANOVA followed by Tukey’s post hoc test. The sample size was determined as a priori to ensure sufficient statistical power to detect meaningful biological differences while minimizing animal using G*Power software (v3.1) based on an expected large effect size (f = 0.40), α = 0.05, and power = 0.80, which yielded a minimum of 7 animals per group. To account for potential experimental loss, 8 rats per group were included. Values of P ˂ 0.05 were considered statistically significant. Effect sizes were calculated to assess the magnitude of differences between groups. Eta squared (η²) was used for ANOVA tests. Institutional review board statement The current study was conducted according to the guidelines of the declaration of Helsinki and ARRIVE (2.0) guidelines that followed the experimental design, bias minimization, sample size and statistical analyses. Rats were randomly divided into 5 groups (4/cage). Target values for temperature and relative humidity were about 22 ± 1 °C and 55 ± 5%, respectively, light- dark (day/night) cycle was achieved. Rats were given drinking tap water and normal experimental pelleted animal food ad libitium. The experimental protocol was approved by Tanta University’s Faculty of Science’s Animal Care Committee with approval number (IACUC-SCI-TU- 0297), Egypt. Acknowledgements The Researchers would like to thank the Deanship of Graduate Studies and Scientific Research at Qassim University (https://www.qu.edu.sa/) for financial support (QU-APC-2026). Author contributions Conceptualization, supervision, investigation, design, methodology, funding acquisition, writing original draft preparation and editing, A.M.A., O.R.A.; Investigation, methodology, data curation, resources, and writing original draft preparation, A.M.S., A.S.A., N.S.A., Validation, formal analysis, methodology, data curation, resources, and writing original draft preparation, A.A.A., S.A., R.M.A., S.A.A., M.A.M., and K.S.E. All authors have read and agreed to the published version of the manuscript. Funding No fund was recievied. Data availability The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.